McCulloch et al., 2024 - Google Patents
The immune checkpoint TIGIT is upregulated on T cells during bacterial infection and is a potential target for immunotherapyMcCulloch et al., 2024
View PDF- Document ID
- 15417443283569536133
- Author
- McCulloch T
- Rossi G
- Miranda‐Hernandez S
- Valencia‐Hernandez A
- Alim L
- Belle C
- Krause A
- Zacchi L
- Lam P
- Nakamura K
- Kupz A
- Wells T
- Souza‐Fonseca‐Guimaraes F
- Publication year
- Publication venue
- Immunology and Cell Biology
External Links
Snippet
Antibiotic resistance is a major public health threat, and alternatives to antibiotic therapy are urgently needed. Immunotherapy, particularly the blockade of inhibitory immune checkpoints, is a leading treatment option in cancer and autoimmunity. In this study, we used …
- 210000001744 T-lymphocyte 0 title abstract description 60
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dixon et al. | TIM-3 restrains anti-tumour immunity by regulating inflammasome activation | |
| Koyama et al. | MHC class II antigen presentation by the intestinal epithelium initiates graft-versus-host disease and is influenced by the microbiota | |
| Perrot et al. | Blocking antibodies targeting the CD39/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies | |
| Sokol et al. | The chemokine receptor CCR8 promotes the migration of dendritic cells into the lymph node parenchyma to initiate the allergic immune response | |
| Ng et al. | RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice | |
| Stark et al. | PI3Kδ hyper-activation promotes development of B cells that exacerbate Streptococcus pneumoniae infection in an antibody-independent manner | |
| Abboud et al. | Inhibition of glycolysis reduces disease severity in an autoimmune model of rheumatoid arthritis | |
| Cooke et al. | The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease | |
| Jung et al. | BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion | |
| Jacobsen et al. | Re‐defining the unique roles for eosinophils in allergic respiratory inflammation | |
| Mattiuz et al. | Type 1 conventional dendritic cells and interferons are required for spontaneous CD4+ and CD8+ T‐cell protective responses to breast cancer | |
| Cheng et al. | Anti‐PD‐L1/TGF‐βR fusion protein (SHR‐1701) overcomes disrupted lymphocyte recovery‐induced resistance to PD‐1/PD‐L1 inhibitors in lung cancer | |
| Wunderlich et al. | A xenograft model of macrophage activation syndrome amenable to anti-CD33 and anti–IL-6R treatment | |
| Henry et al. | Autoantigen-specific B-cell depletion overcomes failed immune tolerance in type 1 diabetes | |
| Merlo et al. | Therapeutic antibody targeting of indoleamine-2, 3-dioxygenase (IDO2) inhibits autoimmune arthritis | |
| KR20240068768A (en) | Non-hla matched humanized nsg mouse model with patient-derived xenograft | |
| Cai et al. | FOXP3+ macrophage represses acute ischemic stroke-induced neural inflammation | |
| Duarte et al. | Modulation of IL-17 and Foxp3 expression in the prevention of autoimmune arthritis in mice | |
| KR20220042056A (en) | Anti-SIGLEC-9 compositions and methods for modulating myeloid cell inflammatory phenotype, and uses thereof | |
| Vikis et al. | Neutrophils are required for 3‐methylcholanthrene‐initiated, butylated hydroxytoluene‐promoted lung carcinogenesis | |
| Sang et al. | Innate and adaptive signals enhance differentiation and expansion of dual-antibody autoreactive B cells in lupus | |
| Uslu et al. | The STING agonist IMSA101 enhances chimeric antigen receptor T cell function by inducing IL-18 secretion | |
| WO2019081591A1 (en) | Nk or t cells and uses thereof | |
| Jin et al. | A single infusion of engineered long-lived and multifunctional T cells confers durable remission of asthma in mice | |
| WO2020008066A1 (en) | Human immune system mouse model |